U.S. regulators launch new review of infant RSV therapies from Merck, Sanofi, and AstraZeneca amid scrutiny by Health Secretary Robert F. Kennedy Jr.
The US Food and Drug Administration (FDA) plans to add a “black box” warning to COVID-19 vaccines, CNN reported, citing two ...
Chinese vaccine company Sinovac Biotech Ltd has announced that the age indications for its trivalent and quadrivalent influenza vaccines have been expanded to include individuals aged 6 months and ...
Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...
Federal officials say the U.S. Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and ...
Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...
FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...
The drugs are essentially laboratory-made versions of natural antibodies that help the immune system fight off RSV. The FDA ...
The FDA has informed Merck, Sanofi and AstraZeneca of the safety investigation into their RSV antibodies, though it remains ...
The agency also is reviewing safety of immunizations for RSV, according to manufacturers of the therapies who have been ...
FDA officials have opened a safety review of two injectable RSV drugs used to protect babies and toddlers from the ...
Merck (MRK)’s stock surged by 41% over the past six months, driven not significantly by revenue, but rather by increased profits and heightened investor confidence. Following crucial Q3 earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback